Physician profile
Thomas Lloyd Simcox
NPI 1124287461
$2,024.29
in general payments reported to CMS, 2019-2025
20 companies · $53.39 in 2025
The $53.39 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $114 · 2021: $630 · 2022: $247 · 2023: $262 · 2024: $362 · 2025: $53.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $990.34 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Janssen Biotech, INC. | $255.99 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Madrigal Pharmaceuticals | $145.43 | 2024 | Rezdiffra |
| Echosens North America, INC. | $115.85 | 2019 | |
| Pfizer INC. | $96.91 | 2021-2025 | |
| Biofire Diagnostics, LLC | $68.05 | 2019 | |
| Intercept Pharmaceuticals, INC. | $45.79 | 2021 | |
| Braintree Laboratories, INC. | $45.26 | 2021-2022 | |
| Celgene Corporation | $44.24 | 2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $32.77 | 2021 | |
| Daiichi Sankyo INC. | $29.65 | 2021 | |
| Allergan, INC. | $25.77 | 2019 | |
| Qol Medical, LLC | $20.36 | 2021 | |
| Ferring Pharmaceuticals INC. | $19.24 | 2023 | Cimzia |
| Gilead Sciences, INC. | $19.18 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $16.01 | 2020 | |
| Merck Sharp & Dohme LLC | $15.54 | 2023 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.84 | 2020 | |
| Ucb, INC. | $12.95 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Simcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.